SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

Mahmoud Al Rifai, L. Kristin Newby, Ajith P. Nair, Arunima Misra, Joseph G. Rogers, Savitri Fedson, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Purpose of Review: In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes. Recent Findings: Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms. Summary: SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.

Original languageEnglish
Pages (from-to)627-634
Number of pages8
JournalCurrent Atherosclerosis Reports
Issue number8
Publication statusPublished - Aug 2022
Externally publishedYes


  • Heart failure (HF)
  • Heart failure with preserved ejection fraction (HFpEF)
  • Heart failure with reduced ejection fraction (HFrEF)
  • Sodium-glucose cotransporter-2 inhibitors (SGLT-2i)


Dive into the research topics of 'SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?'. Together they form a unique fingerprint.

Cite this